Publications by authors named "Tomohiro Katagiri"

Article Synopsis
  • Durvalumab has shown potential to enhance survival in patients with locally advanced non-small cell lung cancer (NSCLC), but the optimal treatment duration is still unclear.
  • This study analyzed 178 patients who received durvalumab after chemoradiotherapy, focusing on the ideal number of treatment cycles and examining survival rates.
  • Results indicated that receiving 20 or more cycles significantly improved progression-free survival and overall survival, suggesting that durvalumab should be administered for more than 6 months for better outcomes.
View Article and Find Full Text PDF

This study aimed to assess recurrence-free survival (RFS) rates and recurrence-related factors of patients who received adjuvant therapy (AT) with radioactive iodine (RAI) for differentiated thyroid cancer (DTC) following thyroidectomy. We evaluated 284 patients who underwent AT between January 2011 and July 2020 at our hospital. Recurrence was defined as visible recurrent lesions on image analysis or need for repeat surgery with pathologically confirmed recurrent lesions.

View Article and Find Full Text PDF

Chemoradiotherapy followed by consolidation durvalumab (CCRT+D) improves survival in patients with stage III non-small-cell lung cancer (NSCLC). We compared recurrence patterns and survival in the CCRT+D and CCRT cohorts. We conducted a multicenter, retrospective study in Japan.

View Article and Find Full Text PDF
Article Synopsis
  • The study evaluated the effectiveness of measuring iodine-131 accumulation using scintigraphy images in patients treated for thyroid cancer, comparing planar images to SPECT images.
  • A total of 72 sets of images were analyzed alongside a reference iodine capsule to determine how image intensity correlates with iodine dosage and radiation dose to the thyroid bed.
  • Results showed a stronger correlation of radiation dose measurement from planar images over SPECT images, with an average thyroid bed radiation dose estimated at 5.9 MBq, allowing for dose estimation in other affected areas.
View Article and Find Full Text PDF

Background: The risk for radiation necrosis is lower in fractionated stereotactic radiotherapy (SRT) than in conventional radiotherapy, and 13-fraction SRT is our method of choice for the treatment of brain metastases ≥ around 2 cm or patients who are expected to have a good prognosis. As 13-fraction SRT lasts for at least 17 days, adaptive radiotherapy based on contrast-enhanced mid-treatment magnetic resonance imaging (MRI) is often necessary for patients undergoing 13-fraction SRT. In this study, we retrospectively analyzed interfractional target changes in patients with brain metastases treated with 13-fraction SRT.

View Article and Find Full Text PDF

Introduction: Data on the risk factors for symptomatic radiation pneumonitis (RP) in non-small-cell lung cancer (NSCLC) patients treated with concurrent chemoradiotherapy (CCRT) and consolidation durvalumab are limited; we aimed to investigate these risk factors.

Materials And Methods: This multicenter retrospective study, conducted at 15 institutions in Japan, included patients who were ≥20 years of age; who started definitive CCRT for NSCLC between July 1, 2018, and July 31, 2019; and who then received durvalumab. The primary endpoint was grade 2 or worse (grade 2+) RP.

View Article and Find Full Text PDF

Objectives: The purpose of this study was to assess the radiological change patterns in skull base meningiomas after conventionally fractionated stereotactic radiotherapy (CFSRT) to determine a simple and valid method to assess the tumor response.

Materials And Methods: Forty-one patients with a benign skull base meningioma treated by CFSRT from March 2007 to August 2015 were retrospectively evaluated. We measured tumor volume (TV), long-axis diameter (LD), and short-axis diameter (SD) on both pre-treatment images and follow-up images of 1, 3, and 5 years after CFSRT, respectively.

View Article and Find Full Text PDF

Background: The prognosis of advanced oral cancer remains dismal. While multimodal therapy is beneficial, maintaining the quality of life of long-term survivors is important. Therefore, risk-adapted treatment regimens need to be designed.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to evaluate the clinical outcomes of adjuvant radioactive iodine (RAI) therapy in thyroid cancer patients using two preparation methods: thyroid hormone withdrawal (THW) and recombinant human thyroid-stimulating hormone (rhTSH).
  • A total of 112 out of 136 selected patients who underwent thyroidectomy for intermediate- to high-risk differentiated thyroid carcinoma were assessed, comparing the effectiveness of the two methods based on the initial achievement rates of the therapy.
  • Results showed that 63.8% of the THW group and 70.8% of the rhTSH group achieved the therapy goal, indicating no significant difference between the groups, but notable differences in TSH levels were observed (THW:
View Article and Find Full Text PDF

Purpose: A new irradiation technique, volumetric-modulated Dynamic WaveArc therapy (VMDWAT), based on sequential non-coplanar trajectories, can be performed using the Vero4DRT. This planning study compared the dose distribution and treatment time between single-isocenter volumetric-modulated arc therapy (VMAT) with multiple straight non-coplanar arcs and single-isocenter VMDWAT in patients with two brain metastases.

Materials And Methods: Twenty patients with two planning target volumes exceeding 2.

View Article and Find Full Text PDF

Objective: This study aimed to compare the clinical outcomes of patients who received radioactive iodine (RAI) ablation after undergoing thyroidectomy for intermediate-to-high-risk differentiated thyroid carcinoma (DTC) according to the American Thyroid Association (ATA) criteria.

Methods: We retrospectively examined patients who underwent RAI ablation for DTC after surgical resection without macroscopic residual lesions or metastatic lesions between December 2011 and August 2016. Among 147 patients who underwent RAI ablation, those whose initial pathological stages or RAI ablation results were unknown and whose distant metastases were confirmed during RAI ablation were excluded.

View Article and Find Full Text PDF

Mono-isocentric volumetric-modulated arc therapy (VMAT) can be used to treat multiple brain metastases. It remains unknown whether mono-isocentric VMAT can improve the dose distribution compared with dual-isocentric dynamic conformal arc therapy (DCAT), especially for two brain metastases. We compared the dose distribution between dual-isocentric DCAT and mono-isocentric VMAT for two large brain metastases, and analyzed the relationship between the distance between the two targets and the difference in dose distribution.

View Article and Find Full Text PDF

Hypoxic and stroma-rich microenvironments, characteristic features of pancreatic cancers, are strongly associated with a poor prognosis. However, whether and how hypoxia increases stromal compartments remain largely unknown. Here, we investigated the potential importance of a master regulator of the cellular adaptive response to hypoxia, hypoxia-inducible factor-1 (HIF-1), in the formation of stroma-rich microenvironments of pancreatic tumors.

View Article and Find Full Text PDF